Literature DB >> 6293977

Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins.

R N Jones, H W Wilson.   

Abstract

Six 7-aminothiazolyl alpha-methoxyimino cephalosporins were found to be most variable in their ability to resist Type IV beta-lactamases (ceftizoxime, most stable and ceftriaxone, least stable), to inhibit Type I beta-lactamases (cefotaxime, the best inhibitor and desacetyl-cefotaxime, the least inhibition), to inhibit Enterobacteriaceae as measured by their minimum inhibitory concentrations (MICs), and in their published serum half-lives. The 3-position substituents appear to exert significant physical-chemical effects that influence the pharmacology, molecular enzyme stability and the antimicrobial activity of these compounds. However, we conclude that these differences are of minimal clinical consequence and that other more relevant factors for in vivo drug selection should be considered, including proven clinical efficacy and cost.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293977     DOI: 10.1007/bf01640880

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Authors:  R Heymès; A Lutz; E Schrinner
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

Authors:  R P Mouton; G P Bongaerts; M van Gestel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime.

Authors:  K P Fu; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

5.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

6.  In vitro evaluation of pyridine-2-azo-p-dimethylaniline cephalosporin, a new diagnostic chromogenic reagent, and comparison with nitrocefin, cephacetrile, and other beta-lactam compounds.

Authors:  R N Jones; H W Wilson; W J Novick
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

7.  In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamases.

Authors:  K Shannon; A King; C Warren; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

8.  Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.

Authors:  P C Fuchs; R N Jones; C Thornsberry; A L Barry; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

9.  In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

Authors:  R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

10.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.

Authors:  R N Jones; A L Barry; C Thornsberry; E H Gerlach; P C Fuchs; T L Gavan; H M Sommers
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

View more
  6 in total

Review 1.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 2.  In vitro activity of cefodizime.

Authors:  H Knothe; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 3.  Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 4.  Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

5.  Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

Review 6.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.